A- A A+

Misplaced Ecstasy? Questioning the Role of Psychedelics as Therapy

(Medscape, 26.10.2017)


Defending MDMA as a Treatment for PTSD

(Medscape, 11.12.2017)


Breakthrough Therapy Designation ensures that FDA will work closely with MAPS to complete Phase 3 trials as efficiently as possible

MAPS and FDA have also reached agreement on design, primary endpoint, and statistical approach for Phase 3 trials

Posttraumatic stress disorder (PTSD) is a serious and life-threatening psychiatric condition with unmet medical need despite available treatments

MAPS is sponsoring two Phase 3 clinical trials of MDMA-assisted psychotherapy in patients with severe PTSD starting in 2018

MAPS, a non-profit research organization, has raised or pledged half of the $25 million estimated cost of these trials, with $12.5 million still needed. (MAPS - Multidisciplinary Association for Psychedelic Studies, 26.08.2017)


Australien. Cracks in the Ice smartphone app provides more Australians with information about crystal methamphetamine (ice)

A smartphone app developed by researchers from the National Drug and Alcohol Research Centre (NDARC) at UNSW and National Drug Research Institute (NDRI) at Curtin University will allow more Australians to access trusted, evidence-based information and resources about crystal methamphetamine (ice). (NDARC/UNSW, 09.01.2018)


Methamphetamin-bezogene Störungen

Clinical practice guideline: Methamphetamine-related disorders

Dtsch Arztebl Int 2017; 114(26): 455-61; DOI: 10.3238/arztebl.2017.0455

Gouzoulis-Mayfrank, Euphrosyne; Härtel-Petri, Roland; Hamdorf, Willem; Havemann-Reinecke, Ursula; Mühlig, Stephan; Wodarz, Norbert


Treatment of methamphetamine addicts in the clinical practice in Germany

Katharina Schoett, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/7582/14H30_4_Katharina Schoett.pptx

Electronic dance music (EDM) parties have historically been high-risk scenes for use of a variety of psychoactive substances. Studies over the past couple of years have found nightclub and festival attendees report high rates of use. These parties are becoming increasingly popular in the U.S., and drug use at such parties has been associated with severe adverse health outcomes, including death. Severity of potential negative health outcomes in EDM environments makes data on both known and unknown drug use critical to further prevention and harm reduction efforts.


Social cognition and interaction in chronic users of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy").

Wunderli MD, Vonmoos M, Treichler L, Zeller C, Dziobek I, Kraemer T, Baumgartner MR, Seifritz E, Quednow BB.

Int J Neuropsychopharmacol. 2017 Oct 26. doi: 10.1093/ijnp/pyx098.


The harms associated with injection of opioids are well documented, but few reports consider the differences in health experienced by those who also inject crystal methamphetamine or ice. Anecdotal reports describe exacerbation of health problems for people who regularly use methamphetamines, and despite the emergence of specific treatments for methamphetamine use, engaging this group of people who inject drugs is challenging. (IDRS - Illicit Drugs Reporting system, Neuseeland, Juli 2017)


Leidet die Empathiefähigkeit bei häufigem Ecstasykonsum?

Ecstasy kann das Bedürfnis verstärken, anderen Menschen nahe zu sein. Doch wie wirkt sich häufiger Ecstasy-Konsum langfristig auf die Empathiefähigkeit aus? Eine Studie aus der Schweiz hat Ecstasykonsumierende hierzu gründlich durchgecheckt. (drugcom.de, 24.11.2017)


Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence.

Ezard N, Dunlop A, Clifford B, Bruno R, Carr A, Bissaker A, Lintzeris N.

BMC Psychiatry. 2016 Dec 1;16(1):428.


After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential “breakthrough therapy” for treatment of posttraumatic stress disorder (PTSD). (American Psychiatric Association, 20.10.2017)


Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.

Ahmadi J, Razeghian Jahromi L.

Trials. 2017 Jun 6;18(1):259. doi: 10.1186/s13063-017-2007-3.


One of the main targets in the war on drugs could well become a drug to treat the scars of war. The U.S. Food and Drug Administration (FDA) has designated 3,4-methylenedioxymethamphetamine (MDMA), better known as the illegal drug ecstasy, a "breakthrough therapy" for posttraumatic stress disorder (PTSD), a status that may lead to faster approval.

The agency has also approved the design for two phase III studies of MDMA for PTSD that would be funded by the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit in Santa Cruz, California. MAPS announced the "breakthrough therapy" designation, made by FDA on 16 August, on its website today; if the group can find the money for the trials, which together could cost an estimated $25 million, they may start next spring and finish by 2021. (Science, 26.08.2017)


A Global Review of the Harm Reduction Response to Amphetamines: A 2015 Update

Sophie Pinkham and Katie Stone

Hrsg.: International Harm Reduction Association, 2015


Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.

Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A.

J Cent Nerv Syst Dis. 2017 Aug 23;9:1179573517728090. doi: 10.1177/1179573517728090.